Rapamycin (Sirolimus) Cost in Kentucky: 2026 Prices, Insurance, and Savings

What Sirolimus Actually Costs at Kentucky Pharmacies in 2026

The average cash price for generic sirolimus across Kentucky retail pharmacies sits at approximately $80 per month in 2026. That figure reflects a dramatic drop from the Pfizer-branded list price of roughly $600 per month, driven by multiple generic entrants that received FDA approval under the Abbreviated New Drug Application pathway.

Pricing varies by pharmacy chain, independent pharmacy, and dose strength. A patient filling a once-weekly 5 mg prescription (roughly 4 to 5 tablets per month) will pay less than someone on a daily transplant regimen requiring 30 tablets. Louisville and Lexington metro-area pharmacies tend to cluster near the $80 average, while smaller rural pharmacies in Eastern Kentucky or the Purchase Area may quote higher prices due to lower dispensing volumes.

GoodRx, RxSaver, and similar coupon aggregators can push the effective price below $60 at select Kentucky locations. These coupons do not count toward insurance deductibles. Costco pharmacies (open to non-members for prescriptions under Kentucky law) frequently offer the lowest posted cash prices for generic sirolimus statewide.

Pfizer Brand vs. Generic vs. Compounded: A Price Breakdown

Three distinct product tiers exist in Kentucky, and each carries a different cost structure.

Pfizer brand (Rapamune): The wholesale acquisition cost remains near $600 per month. Few Kentucky patients pay this amount directly because most commercial plans that cover sirolimus reimburse at generic rates, but patients without insurance who request the brand specifically will face this figure.

Generic sirolimus tablets: Manufactured by Greenstone, Biocon, and others, these carry average cash prices around $80 per month. Bioequivalence to Rapamune was established through the FDA's Orange Book standards, meaning therapeutic equivalence is confirmed.

Compounded sirolimus capsules (503A pharmacies): Kentucky-licensed 503A compounding pharmacies can prepare sirolimus capsules in custom doses (often 1 mg, 2 mg, 3 mg, or 5 mg). This costs approximately $120 per month. Compounding is particularly useful for once-weekly longevity protocols that require dose strengths not commercially available. Kentucky permits 503A compounding under KRS 315.010 and federal section 503A of the FD&C Act, provided a valid patient-specific prescription exists.

The cost-per-milligram math favors generics for standard doses. Compounding becomes cost-competitive only when a prescriber orders a non-standard strength that would require splitting or combining commercial tablets.

Kentucky Medicaid and Sirolimus Coverage

Kentucky Medicaid does not cover sirolimus when prescribed off-label for longevity or anti-aging purposes. This applies to both fee-for-service Medicaid and the managed care organizations (MCOs) administering Kentucky's Medicaid program: Aetna Better Health, Anthem, Humana Healthy Horizons, Molina, and WellCare.

For FDA-approved indications (prophylaxis of organ rejection in renal transplant recipients aged 13 and older), Kentucky Medicaid does cover sirolimus with prior authorization. The FDA-approved labeling specifies that sirolimus is indicated in combination with cyclosporine and corticosteroids for kidney transplant patients. Coverage under this indication requires documentation from a transplant center and usually includes step-therapy through mycophenolate first.

Patients on Kentucky Medicaid who want sirolimus for off-label longevity use will need to pay cash. At $80 per month for generics, this falls below the cost of many supplements that Medicaid also does not cover.

Insurance Coverage Beyond Medicaid

Commercial insurance plans in Kentucky vary widely on sirolimus coverage. The picture breaks down by use case.

Transplant indication: Most commercial plans, including those sold on Kynect (Kentucky's state-based health insurance exchange), cover sirolimus for transplant rejection prophylaxis. Copays typically range from $10 to $50 per month on preferred generic tiers. Plans from Anthem, Humana, CareSource, and Aetna all list generic sirolimus on their Kentucky formularies.

Off-label longevity use: No major commercial insurer in Kentucky covers sirolimus specifically for longevity or aging indications as of 2026. Physicians may attempt prior authorization citing emerging evidence, but approval rates remain low. The Endocrine Society's clinical practice guidelines have not issued a recommendation for sirolimus as a longevity agent, which makes insurance appeals difficult.

Medicare Part D: Generic sirolimus is listed on most Medicare Part D formularies in Kentucky for transplant use. Off-label prescriptions may be rejected at the pharmacy counter. Medicare beneficiaries paying cash for off-label use should compare Part D pricing against GoodRx coupons, as the cash price is sometimes lower than the Part D copay during the coverage gap.

A 2023 analysis published in the Journal of the American Geriatrics Society found that fewer than 3% of off-label mTOR inhibitor prescriptions received commercial insurance reimbursement nationally [1]. Kentucky tracks close to this figure.

The Clinical Evidence Behind Longevity Dosing

Patients researching sirolimus cost in Kentucky are often considering once-weekly, low-dose protocols based on emerging longevity research. The evidence base is growing but still consists of small trials.

The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024, enrolled 150 healthy adults aged 50 to 85 and randomized them to rapamycin 5 mg weekly or placebo for 48 weeks [2]. Primary outcomes focused on safety, with secondary endpoints including visceral fat, bone density, and functional measures. The trial established that once-weekly rapamycin 5 mg was well tolerated in this population, with no significant increase in infections or metabolic adverse events compared to placebo.

An earlier randomized trial by Mannick et al. (2014) in Science Translational Medicine demonstrated that the rapalog everolimus improved immune function in elderly volunteers, as measured by response to influenza vaccination (N=218) [3]. While this trial used everolimus rather than sirolimus, it provided mechanistic support for mTOR inhibition as a strategy to reverse age-related immune decline.

The National Institute on Aging Interventions Testing Program showed that rapamycin extended median lifespan by 9% in male mice and 14% in female mice when started at 20 months of age [4]. These results, while preclinical, generated the clinical interest now driving human trials.

Dr. Matt Kaeberlein, former director of the University of Washington Healthy Aging and Longevity Research Institute, has noted: "Rapamycin is the most reproducible pharmacological intervention for extending lifespan in laboratory animals. The question is whether low-dose, intermittent protocols in humans can capture benefits while avoiding immunosuppressive side effects."

The Endocrine Society and the American Federation for Aging Research have both called for larger, longer randomized controlled trials before recommending rapamycin for general longevity use [5].

How Telehealth Works for Kentucky Sirolimus Prescriptions

Kentucky permits telehealth prescribing of sirolimus statewide. This became practical after Kentucky enacted SB 150 (2020), which removed previous restrictions requiring an in-person visit before a telehealth prescription. The law applies to all Schedule VI and non-scheduled medications, and sirolimus is not a controlled substance.

Several telehealth platforms now prescribe sirolimus for off-label longevity use to Kentucky residents. A typical telehealth consultation costs $100 to $250 for the initial visit and $50 to $150 for follow-ups. Lab monitoring (CBC, lipid panel, fasting glucose, hepatic panel) is recommended at baseline and every 3 to 6 months.

The prescription can be sent to any Kentucky-licensed retail pharmacy or to a 503A compounding pharmacy licensed in the state. Patients in rural Kentucky counties, where the nearest retail pharmacy may be 20 or more miles away, benefit from mail-order options that pair with telehealth prescriptions.

Dr. Peter Attia, a physician known for his work in applied longevity medicine, has stated: "The combination of telehealth prescribing and affordable generic pricing has made rapamycin accessible in states like Kentucky where specialist visits previously required significant travel."

Is Compounded Sirolimus Legal in Kentucky?

Yes. Compounded sirolimus is legal in Kentucky when dispensed by a pharmacy operating under a valid 503A license. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound medications based on individual patient prescriptions, provided they do not essentially copy a commercially available product in the same strength and dosage form.

Kentucky's Board of Pharmacy regulates compounding through 201 KAR 2:076. Key requirements include a valid prescription from a licensed prescriber for a specific patient, a compounding pharmacy that holds an active Kentucky license, adherence to USP 795 standards for non-sterile compounding, and documentation that the compounded product addresses a clinical need not met by commercially available products.

In practice, the "clinical need" requirement is typically met when a prescriber orders a dose (such as 3 mg or 4 mg) that is not available as a commercial tablet. Sirolimus is commercially available as 0.5 mg, 1 mg, and 2 mg tablets. A once-weekly 5 mg dose requires splitting or combining tablets, which gives compounding pharmacies a legitimate basis to prepare custom capsules.

Both Louisville and Lexington have multiple 503A pharmacies that compound sirolimus. Several out-of-state compounding pharmacies also ship to Kentucky addresses, provided they hold a non-resident pharmacy license from the Kentucky Board of Pharmacy.

Discount Programs and Savings Cards

Several pathways exist to reduce sirolimus costs for Kentucky patients paying out of pocket.

Manufacturer savings cards: Pfizer offers a copay savings card for Rapamune that can reduce the out-of-pocket cost to as low as $0 for commercially insured patients. This card does not apply to cash-paying patients, Medicaid beneficiaries, or Medicare Part D enrollees. Details are available through the Pfizer patient assistance page.

Generic manufacturer rebates: Some generic sirolimus manufacturers offer limited rebate programs through pharmacy benefit managers. These are not widely advertised but can be accessed through the dispensing pharmacy.

GoodRx and RxSaver coupons: These platforms aggregate negotiated prices from pharmacy benefit managers and can bring the cost of generic sirolimus to $50 to $70 per month at specific Kentucky pharmacies. Kroger, Walmart, and CVS locations in Kentucky frequently accept these coupons.

Patient assistance programs: Pfizer's Pfizer RxPathways program provides free or discounted Rapamune to uninsured or underinsured patients who meet income requirements (generally below 400% of the federal poverty level). The application requires documentation of income and a prescription from a licensed provider.

Health savings accounts (HSAs) and flexible spending accounts (FSAs): Sirolimus prescriptions, whether brand, generic, or compounded, are eligible HSA/FSA expenses when accompanied by a valid prescription. Kentucky residents with high-deductible health plans can use pre-tax HSA dollars to cover the cost.

What Lab Monitoring Costs to Expect

Sirolimus prescriptions, particularly for off-label longevity use, require periodic lab monitoring that adds to the total cost of therapy. Kentucky patients should budget for baseline labs ($150 to $300 at cash-pay rates through Quest or Labcorp) and follow-up panels every 3 to 6 months.

Standard monitoring includes a complete blood count, comprehensive metabolic panel, fasting lipid panel, and fasting glucose or HbA1c. Some clinicians also order sirolimus trough levels, particularly during dose titration, at a cost of approximately $50 to $100 per draw. A 2022 review in the Journal of Clinical Pharmacology noted that trough monitoring is standard for transplant dosing but has not been validated for once-weekly longevity protocols.

Telehealth platforms that prescribe sirolimus in Kentucky often bundle lab orders at discounted rates. Several partner with national lab chains to offer panels for $75 to $150, which can meaningfully reduce the annualized cost of therapy.

Total Annual Cost Estimate for Kentucky Patients

A Kentucky patient on a once-weekly generic sirolimus protocol can expect to pay approximately $960 to $1,200 per year for medication alone ($80 per month for generic tablets). Adding telehealth visits ($200 to $500 per year) and lab monitoring ($300 to $600 per year) brings the all-in annual cost to roughly $1,460 to $2,300.

Compounded sirolimus raises the medication cost to approximately $1,440 per year. Patients using brand Rapamune without insurance would face $7,200 or more annually, making it impractical for most self-pay patients.

These figures place rapamycin therapy in a similar cost range to other self-pay longevity interventions in Kentucky, such as NAD+ infusions ($250 to $500 per session) or growth hormone peptide therapy ($150 to $300 per month).